Your browser doesn't support javascript.
loading
ECTRIMS/EAN consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs.
Otero-Romero, Susana; Lebrun-Frénay, Christine; Reyes, Saúl; Amato, Maria Pia; Campins, Magda; Farez, Mauricio; Filippi, Massimo; Hacohen, Yael; Hemmer, Bernhard; Juuti, Rosa; Magyari, Melinda; Oreja-Guevara, Celia; Siva, Aksel; Vukusic, Sandra; Tintoré, Mar.
Afiliación
  • Otero-Romero S; Department of Preventive Medicine and Epidemiology, Vall d'Hebron Barcelona Hospital, Barcelona, Spain Multiple Sclerosis Centre of Catalonia (Cemcat), Vall d'Hebron Barcelona Hospital, Barcelona, Spain.
  • Lebrun-Frénay C; CRC-SEP Nice, CHU de Nice, Universite Nice Cote d'Azur UR2CA-URRIS, Nice, France.
  • Reyes S; Fundación Santa Fe de Bogotá, Bogotá, Colombia School of Medicine, Universidad de los Andes, Bogotá, Colombia Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.
  • Amato MP; Department NEUROFARBA, University of Florence, Florence, Italy IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy.
  • Campins M; Department of Preventive Medicine and Epidemiology, Vall d'Hebron Barcelona Hospital, Barcelona, Spain.
  • Farez M; Centro para la Investigación de Enfermedades Neuroinmunológicas (CIEN), FLENI, Buenos Aires, Argentina.
  • Filippi M; Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy Neurology Unit, Neurorehabilitation Unit, and Neurophysiology Service, IRCCS San Raffaele Scientific Institute, Milan, Italy Vita-Salute San Raffaele University, Milan, Italy.
  • Hacohen Y; Department of Paediatric Neurology, Great Ormond Street Hospital for Children, London, UK Department of Neuroinflammation, Queen Square Multiple Sclerosis Centre, UCL Institute of Neurology, London, UK.
  • Hemmer B; Department of Neurology, Klinikum Rechts der Isar, School of Medicine, Technical University of Munich, Munich, Germany Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.
  • Juuti R; Multiple Sclerosis International Federation, London, UK.
  • Magyari M; Department of Neurology, Danish Multiple Sclerosis Center and the Danish Multiple Sclerosis Registry, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.
  • Oreja-Guevara C; Department of Neurology, Hospital Clínico San Carlos, IdISSC, Departamento de Medicina, Universidad Complutense, Madrid, Spain.
  • Siva A; Department of Neurology, School of Medicine, Istanbul University Cerrahpasa, Cerrahpasa, Istanbul, Turkey.
  • Vukusic S; Service de Neurologie, Sclérose en Plaques, Pathologies de la Myéline et Neuro-inflammation, Centre de Référence des Maladies Inflammatoires Rares du Cerveau et de la Moelle, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Lyon, France.
  • Tintoré M; Centre des Neurosciences de Lyon, Observatoire Français de la Sclérose en Plaques, INSERM 1028 et CNRS UMR5292, Lyon, France Université Claude Bernard Lyon 1, Faculté de Médecine Lyon Est, Lyon, France.
Mult Scler ; 29(8): 904-925, 2023 07.
Article en En | MEDLINE | ID: mdl-37293841
BACKGROUND: With the new highly active drugs available for people with multiple sclerosis (pwMS), vaccination becomes an essential part of the risk management strategy. OBJECTIVE: To develop a European evidence-based consensus for the vaccination strategy of pwMS who are candidates for disease-modifying therapies (DMTs). METHODS: This work was conducted by a multidisciplinary working group using formal consensus methodology. Clinical questions (defined as population, interventions, and outcomes) considered all authorized DMTs and vaccines. A systematic literature search was conducted and quality of evidence was defined according to the Oxford Centre for Evidence-Based Medicine Levels of Evidence. The recommendations were formulated based on the quality of evidence and the risk-benefit balance. RESULTS: Seven questions, encompassing vaccine safety, vaccine effectiveness, global vaccination strategy and vaccination in sub-populations (pediatric, pregnant women, elderly and international travelers) were considered. A narrative description of the evidence considering published studies, guidelines, and position statements is presented. A total of 53 recommendations were agreed by the working group after three rounds of consensus. CONCLUSION: This first European consensus on vaccination in pwMS proposes the best vaccination strategy according to current evidence and expert knowledge, with the goal of homogenizing the immunization practices in pwMS.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Esclerosis Múltiple Tipo de estudio: Guideline / Systematic_reviews Límite: Aged / Child / Female / Humans / Pregnancy Idioma: En Revista: Mult Scler Asunto de la revista: NEUROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Esclerosis Múltiple Tipo de estudio: Guideline / Systematic_reviews Límite: Aged / Child / Female / Humans / Pregnancy Idioma: En Revista: Mult Scler Asunto de la revista: NEUROLOGIA Año: 2023 Tipo del documento: Article País de afiliación: España Pais de publicación: Reino Unido